nodes	percent_of_prediction	percent_of_DWPC	metapath
Lorazepam—Pulmonary haemorrhage—Fludarabine—lymphatic system cancer	0.0484	0.0484	CcSEcCtD
Lorazepam—Pulmonary haemorrhage—Vincristine—lymphatic system cancer	0.0296	0.0296	CcSEcCtD
Lorazepam—Pericardial effusion—Fludarabine—lymphatic system cancer	0.0268	0.0268	CcSEcCtD
Lorazepam—Brain oedema—Carmustine—lymphatic system cancer	0.0246	0.0246	CcSEcCtD
Lorazepam—Hypoxia—Fludarabine—lymphatic system cancer	0.0173	0.0173	CcSEcCtD
Lorazepam—Obstructive airways disorder—Methotrexate—lymphatic system cancer	0.0143	0.0143	CcSEcCtD
Lorazepam—Inappropriate antidiuretic hormone secretion—Vincristine—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Lorazepam—Respiratory failure—Fludarabine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Lorazepam—Myoclonus—Vincristine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Lorazepam—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Lorazepam—Coma—Fludarabine—lymphatic system cancer	0.01	0.01	CcSEcCtD
Lorazepam—Paralysis—Vincristine—lymphatic system cancer	0.00966	0.00966	CcSEcCtD
Lorazepam—Stupor—Carmustine—lymphatic system cancer	0.00942	0.00942	CcSEcCtD
Lorazepam—Jaundice—Mechlorethamine—lymphatic system cancer	0.00925	0.00925	CcSEcCtD
Lorazepam—Sleep disorder—Fludarabine—lymphatic system cancer	0.00922	0.00922	CcSEcCtD
Lorazepam—Aggression—Bleomycin—lymphatic system cancer	0.00917	0.00917	CcSEcCtD
Lorazepam—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00885	0.00885	CcSEcCtD
Lorazepam—Injection site pain—Carmustine—lymphatic system cancer	0.00861	0.00861	CcSEcCtD
Lorazepam—Visual disturbance—Fludarabine—lymphatic system cancer	0.00842	0.00842	CcSEcCtD
Lorazepam—Liver function test abnormal—Teniposide—lymphatic system cancer	0.00838	0.00838	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Fludarabine—lymphatic system cancer	0.00798	0.00798	CcSEcCtD
Lorazepam—Pericardial effusion—Methotrexate—lymphatic system cancer	0.00794	0.00794	CcSEcCtD
Lorazepam—Cystitis noninfective—Bleomycin—lymphatic system cancer	0.00787	0.00787	CcSEcCtD
Lorazepam—Cystitis—Bleomycin—lymphatic system cancer	0.00778	0.00778	CcSEcCtD
Lorazepam—Thinking abnormal—Carmustine—lymphatic system cancer	0.00768	0.00768	CcSEcCtD
Lorazepam—Alopecia—Mechlorethamine—lymphatic system cancer	0.00753	0.00753	CcSEcCtD
Lorazepam—Leukocytosis—Carmustine—lymphatic system cancer	0.00748	0.00748	CcSEcCtD
Lorazepam—Pancytopenia—Teniposide—lymphatic system cancer	0.00745	0.00745	CcSEcCtD
Lorazepam—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Lorazepam—Bladder pain—Bleomycin—lymphatic system cancer	0.00728	0.00728	CcSEcCtD
Lorazepam—Injection site reaction—Carmustine—lymphatic system cancer	0.00699	0.00699	CcSEcCtD
Lorazepam—Respiratory failure—Vincristine—lymphatic system cancer	0.00684	0.00684	CcSEcCtD
Lorazepam—Urinary incontinence—Carmustine—lymphatic system cancer	0.00679	0.00679	CcSEcCtD
Lorazepam—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.00679	0.00679	CcSEcCtD
Lorazepam—Vertigo—Mechlorethamine—lymphatic system cancer	0.00666	0.00666	CcSEcCtD
Lorazepam—Pancytopenia—Fludarabine—lymphatic system cancer	0.00655	0.00655	CcSEcCtD
Lorazepam—Disorientation—Bleomycin—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Lorazepam—Coma—Carmustine—lymphatic system cancer	0.00643	0.00643	CcSEcCtD
Lorazepam—Coma—Vincristine—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Lorazepam—Mental disability—Carmustine—lymphatic system cancer	0.0061	0.0061	CcSEcCtD
Lorazepam—Infection—Mechlorethamine—lymphatic system cancer	0.00601	0.00601	CcSEcCtD
Lorazepam—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Lorazepam—Chills—Teniposide—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Lorazepam—Arrhythmia—Teniposide—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Lorazepam—Alopecia—Teniposide—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Lorazepam—Amnesia—Carmustine—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Lorazepam—Visual impairment—Fludarabine—lymphatic system cancer	0.00532	0.00532	CcSEcCtD
Lorazepam—Hypoxia—Methotrexate—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Lorazepam—Hyponatraemia—Carmustine—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Lorazepam—Diplopia—Carmustine—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Lorazepam—Agitation—Teniposide—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Lorazepam—Chills—Fludarabine—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Lorazepam—Arrhythmia—Fludarabine—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Lorazepam—Hyponatraemia—Vincristine—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Lorazepam—Alopecia—Fludarabine—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Lorazepam—Pancytopenia—Bleomycin—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Lorazepam—Ataxia—Carmustine—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Lorazepam—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Lorazepam—Hypertension—Teniposide—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Lorazepam—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Lorazepam—Paralysis—Methotrexate—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Lorazepam—Cardiac arrest—Vincristine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Lorazepam—Ataxia—Vincristine—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Lorazepam—Confusional state—Teniposide—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Lorazepam—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Lorazepam—Infection—Teniposide—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Lorazepam—Agitation—Fludarabine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Lorazepam—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Lorazepam—Stupor—Methotrexate—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Lorazepam—Tachycardia—Teniposide—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Lorazepam—Pancytopenia—Carmustine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Lorazepam—Hypotension—Teniposide—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Lorazepam—Convulsion—Fludarabine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Lorazepam—Pancytopenia—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Lorazepam—Confusional state—Fludarabine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Lorazepam—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Lorazepam—Infection—Fludarabine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Lorazepam—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Lorazepam—Vomiting—Mechlorethamine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Lorazepam—Apnoea—Methotrexate—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Lorazepam—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Lorazepam—Rash—Mechlorethamine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Lorazepam—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Lorazepam—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Lorazepam—Feeling abnormal—Teniposide—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Lorazepam—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Lorazepam—Chills—Bleomycin—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Lorazepam—Nausea—Mechlorethamine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Lorazepam—Alopecia—Bleomycin—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Lorazepam—Jaundice—Mitoxantrone—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Lorazepam—Erythema—Bleomycin—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Lorazepam—Hallucination—Carmustine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Lorazepam—Dysarthria—Methotrexate—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Lorazepam—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Lorazepam—Visual impairment—Carmustine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Lorazepam—Fatigue—Fludarabine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Lorazepam—Hallucination—Vincristine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Lorazepam—Pain—Fludarabine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Lorazepam—Constipation—Fludarabine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Lorazepam—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Lorazepam—Respiratory failure—Methotrexate—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Lorazepam—Hypersensitivity—Teniposide—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Lorazepam—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Lorazepam—Asthenia—Teniposide—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Lorazepam—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Lorazepam—Arrhythmia—Carmustine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Lorazepam—Cystitis—Methotrexate—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Lorazepam—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Lorazepam—Alopecia—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Lorazepam—Erythema—Carmustine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Lorazepam—Alopecia—Vincristine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Lorazepam—Coma—Methotrexate—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Lorazepam—Chills—Mitoxantrone—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Lorazepam—Bladder pain—Methotrexate—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Lorazepam—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Lorazepam—Alopecia—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Lorazepam—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Lorazepam—Confusional state—Bleomycin—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Lorazepam—Vision blurred—Carmustine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Lorazepam—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Lorazepam—Tremor—Carmustine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Lorazepam—Erythema—Mitoxantrone—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Lorazepam—Infection—Bleomycin—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Lorazepam—Vomiting—Teniposide—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Lorazepam—Agitation—Carmustine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Lorazepam—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Lorazepam—Asthenia—Fludarabine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Lorazepam—Rash—Teniposide—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Lorazepam—Dermatitis—Teniposide—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Lorazepam—Headache—Teniposide—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Lorazepam—Agitation—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Lorazepam—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Lorazepam—Hypotension—Bleomycin—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Lorazepam—Convulsion—Carmustine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Lorazepam—Hypertension—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Lorazepam—Nausea—Teniposide—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Lorazepam—Vertigo—Vincristine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Lorazepam—Convulsion—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Lorazepam—Hypertension—Vincristine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Lorazepam—Confusional state—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Lorazepam—Visual disturbance—Methotrexate—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Lorazepam—Infection—Carmustine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Lorazepam—Vomiting—Fludarabine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Lorazepam—Convulsion—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Lorazepam—Rash—Fludarabine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Lorazepam—Dermatitis—Fludarabine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Lorazepam—Hypertension—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Lorazepam—Pain—Bleomycin—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Lorazepam—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Lorazepam—Headache—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Lorazepam—Tachycardia—Carmustine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Lorazepam—Lethargy—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Lorazepam—Infection—Vincristine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Lorazepam—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Lorazepam—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Lorazepam—Confusional state—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Lorazepam—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Lorazepam—Hypotension—Carmustine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Lorazepam—Nausea—Fludarabine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Lorazepam—Infection—Mitoxantrone—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Lorazepam—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Lorazepam—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Lorazepam—Irritability—Methotrexate—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Lorazepam—Hypotension—Vincristine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Lorazepam—Somnolence—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Lorazepam—Ataxia—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Lorazepam—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Lorazepam—Hypotension—Mitoxantrone—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Lorazepam—Pain—Carmustine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Lorazepam—Constipation—Carmustine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Lorazepam—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Lorazepam—Somnolence—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Lorazepam—Feeling abnormal—Carmustine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Lorazepam—Fatigue—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Lorazepam—Asthenia—Bleomycin—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Lorazepam—Pain—Vincristine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Lorazepam—Constipation—Vincristine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Lorazepam—Fatigue—Mitoxantrone—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Lorazepam—Pain—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Lorazepam—Constipation—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Lorazepam—Pancytopenia—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Lorazepam—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Lorazepam—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Lorazepam—Hypersensitivity—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Lorazepam—Vomiting—Bleomycin—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Lorazepam—Drowsiness—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Lorazepam—Rash—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Lorazepam—Dermatitis—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Lorazepam—Asthenia—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Lorazepam—Hypersensitivity—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Lorazepam—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Lorazepam—Asthenia—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Lorazepam—Nausea—Bleomycin—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Lorazepam—Agranulocytosis—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Lorazepam—Asthenia—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Lorazepam—Dizziness—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Lorazepam—Vomiting—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Lorazepam—Dizziness—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Lorazepam—Rash—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Lorazepam—Dermatitis—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Lorazepam—Visual impairment—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Lorazepam—Headache—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Lorazepam—Vomiting—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Lorazepam—Rash—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Lorazepam—Dermatitis—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Lorazepam—Headache—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Lorazepam—Nausea—Carmustine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Lorazepam—Vomiting—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Lorazepam—Rash—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Lorazepam—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Lorazepam—Chills—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Lorazepam—Headache—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Lorazepam—Alopecia—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Lorazepam—Erythema—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Lorazepam—Nausea—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Lorazepam—Nausea—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Lorazepam—Vision blurred—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Lorazepam—Vertigo—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Lorazepam—Convulsion—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Lorazepam—Confusional state—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Lorazepam—Infection—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Lorazepam—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Lorazepam—Hypotension—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Lorazepam—Somnolence—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Lorazepam—Fatigue—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Lorazepam—Pain—Methotrexate—lymphatic system cancer	0.000994	0.000994	CcSEcCtD
Lorazepam—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000958	0.000958	CcSEcCtD
Lorazepam—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Lorazepam—Asthenia—Methotrexate—lymphatic system cancer	0.000834	0.000834	CcSEcCtD
Lorazepam—Dizziness—Methotrexate—lymphatic system cancer	0.000769	0.000769	CcSEcCtD
Lorazepam—Vomiting—Methotrexate—lymphatic system cancer	0.000739	0.000739	CcSEcCtD
Lorazepam—Rash—Methotrexate—lymphatic system cancer	0.000733	0.000733	CcSEcCtD
Lorazepam—Dermatitis—Methotrexate—lymphatic system cancer	0.000732	0.000732	CcSEcCtD
Lorazepam—Headache—Methotrexate—lymphatic system cancer	0.000728	0.000728	CcSEcCtD
Lorazepam—Nausea—Methotrexate—lymphatic system cancer	0.00069	0.00069	CcSEcCtD
